Anzemet

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2014
0119952014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
 
Is this relevant?
Review
2007
Review
2007
Dolasetron (Anzemet) overdose is uncommon, and, to our knowledge, this is the only case report of an intentional overdose… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Review
2005
Review
2005
01. Squamous cell carcinomas of the head and neck generally arise from the a. Submucosal tissues. b. Major and minor salivary… (More)
Is this relevant?
Review
2003
Review
2003
Emesis is a major obstacle to cancer chemotherapy. Patients indicate that nausea and vomiting are a substantial concern when… (More)
Is this relevant?
Review
2000
Review
2000
Nausea and vomiting continue to rank as important side effects for cancer patients receiving chemotherapy. The class of drugs… (More)
Is this relevant?
1999
1999
Dolasetron mesylate (MDL 73,147, Anzemet, Hoechst Marion Roussel, Kansas City, MO) is a 5-HT ( 3 ) receptor antagonist undergoing… (More)
Is this relevant?
1998
1998
Anzemet (dolasetron mesylate) is being developed for the prevention of chemotherapy-induced emesis and postoperative nausea and… (More)
Is this relevant?
1997
1997
1. Dolasetron (Anzemet) is a potent and selective 5-HT3 receptor antagonist which is rapidly and extensively reduced to yield its… (More)
Is this relevant?
1996
1996
Dolasetron mesylate (MDL 73,147EF, Anzemet; Hoechst Marion Roussel, Laval, Canada) is a 5-HT3 receptor antagonist undergoing… (More)
Is this relevant?
1995
1995
Dolasetron, Anzemet, a 5-hydroxytryptamine receptor antagonist, is under investigation as an antiemetic agent. The keto-reduced… (More)
Is this relevant?